실적분석 2026년 8월 5일

Kymera Therapeutics ($KYMR) Q2 2026 Earnings Analysis — Collaboration Revenue Crushes Consensus, Clinical Timeline Accelerates, Flat After-Hours

Earnings Scorecard

Revenue: $65 million (YoY roughly +466%, estimate $32.17 million) ✅ Beat

EPS: GAAP loss per share of $0.62 (adjusted estimate -$0.74 · not directly comparable due to different accounting bases)

Guidance: Clinical timeline upgrade (acceleration) — KT-621 atopic dermatitis Phase 2b primary readout in late 2026 (6 months ahead of prior mid-2027), cash runway through 2029

Stock reaction: After-hours +0.13% ($104.53) — as of 08-05 20:26 KST

What Went Well

Collaboration revenue beat: Q2 collaboration revenue of $65 million significantly exceeded the $32.17 million estimate

Clinical timeline acceleration: KT-621 atopic dermatitis Phase 2b enrollment completed approximately 6 months early, with readout timing moved up to late 2026

Strong cash position: Cash and investments of approximately $1.5 billion as of end of June 2026, with runway through 2029

Kymera is a clinical-stage biotech with no products on the market yet, so the bulk of this quarter's revenue came from partner agreements. Gilead exercised its exclusive license option on KT-200, an oral CDK2 molecular glue degrader candidate, recognizing $45 million, while Sanofi recognized a $20 million milestone on the first dosing of KT-485, a second-generation IRAK4 degrader. Together, these pushed collaboration revenue sharply higher YoY from roughly $11.5 million.

Pipeline execution was also a highlight. The company finished enrollment in the BROADEN2 Phase 2b trial of lead candidate KT-621 (a STAT6 degrader) in moderate-to-severe atopic dermatitis about six months ahead of the original timeline, moving the primary readout from mid-2027 to late 2026. Management also set a goal of initiating a Phase 3 by mid-2027 following regulatory discussions. Net loss attributable to common shareholders narrowed to $61.21 million from $76.61 million in the prior-year period, and the cash runway was said to extend through 2029, covering multiple clinical inflection points.

What Fell Short

One-time revenue dependency: The entire $65 million is option and milestone income, with no product revenue

R&D surge: Q2 R&D expense of $119.5 million (vs. $78.4 million in the prior-year period)

Still loss-making: Net loss attributable to common shareholders of $61.21 million, with no approved drugs

The headline beat looks impressive, but the underlying content is not sustainable product revenue. The Gilead option exercise fee and Sanofi's first-dosing milestone landed in the same quarter, so it is hard to argue the same scale will repeat next quarter. When evaluating clinical-stage biotech earnings, it is more useful to look at both how much cash remains and when the next clinical readout is coming, rather than "revenue growth" alone.

The cost burden is also growing. R&D expense rose sharply YoY, driven by the STAT6 program, platform and early-stage discovery work, and organizational expansion, while SG&A climbed to $21.1 million. Management says the approximately $1.5 billion in cash gets the company through 2029, but spending can accelerate as the pipeline moves into later-stage trials. Ultimately, the investment debate is less about quarterly P&L and more about the late-2026 KT-621 atopic dermatitis Phase 2b data and the potential path to Phase 3 afterwards.

What Management Said

Management framed the moment as a "pivotal period of execution," emphasizing that multiple clinical-stage programs are advancing simultaneously. CEO Nello Mainolfi characterized the early completion of BROADEN2 enrollment as evidence of physician and patient demand for an oral therapy and of the team's execution, noting that the accelerated timeline allows new options to reach patients sooner. The tone was clearly focused on execution across the portfolio — KT-621 in atopic dermatitis and asthma, KT-579 in immune diseases such as lupus, and partner programs.

On the financial side, the company provided cash runway guidance (through 2029) and a clinical timeline rather than traditional revenue and EPS guidance. KT-621 atopic dermatitis Phase 2b primary readout is slated for late 2026, KT-621 asthma Phase 2b (BREATH) data for late 2027, and KT-579 healthy-volunteer Phase 1 data for Q4 2026. The investment narrative is centered less on numerical guidance and more on "when does which clinical card get flipped."

Market Reaction and What to Watch Next

The pre-market earnings and pipeline update came out, but the after-hours reaction was essentially flat. The BROADEN2 enrollment completion and the Gilead and Sanofi milestones were already known from the prior April–June window, so this release read less as a fresh surprise and more as a numerical confirmation of existing expectations. The collaboration revenue beat is positive but one-off, and what the market is really waiting for is efficacy and safety data.

Investor focus is likely to shift from near-term stock moves to the next 12–18 months of clinical milestones. The cash cushion looks ample, limiting the pressure for an imminent raise, but as R&D rises and later-stage trial costs layer in, the pace of loss reduction may stay limited.

Watch for the efficacy and safety contours of the BROADEN2 (atopic dermatitis Phase 2b) primary readout for KT-621, expected late 2026.

Watch for the KT-579 (IRF5) healthy-volunteer Phase 1 data in Q4 2026 and whether the planned proof-of-concept trial in lupus patients kicks off.

Track quarterly R&D and cash burn pace, and whether the 2029 runway assumption remains intact.